Foghorn management will review updates for FHD-909, a potential first-in-class selective SMARCA2 inhibitor, including new preclinical combination data being presented at the 2025 AACR Annual Meeting.

The company’s advancements in SMARCA2 degrader therapies and other innovative treatments reflect its ongoing commitment to addressing high-unmet needs in cancer care. Clinical Pipeline Updates ...

Prelude Therapeutics Inc. described the discovery of PRT-3789, a first-in-human, highly potent and selective SMARCA2-targeted protein degrader, for the potential treatment of cancer. BioWorld Science ...

Foghorn Therapeutics Inc. announced continued enrollment in its Phase 1 trial for FHD-909, a first-in-class oral selective SMARCA2 inhibitor targeting SMARCA4 mutated cancers, particularly non ...

INDIANAPOLIS, March 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be ...

Company to share new preclinical combination datafor FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small ...

Presentation Title: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitors Abstract Number: 3779 Session Date & Time ...

Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target ...